In addition, some patients with 1p/19q co-deleted gliomas developed recurrence within a few years and these gliomas lacked TP53 mutations, suggesting the presence of other genes that contribute to a poor prognoses in patients with IDH mutant gliomas. The gene discussed is IDH2; the disease is central nervous system cancer.